blokes bpc 157 Peptide BPC-157 What is BPC-157? | Everything

Perspectives for the development of CD38-specific heavy chain antibodies as therapeutics for multiple myeloma

we all want to go back to what we were instantly unfortunately it doesn't work like that

The top dose produced 20.9% average weight loss over 72 weeks and 20.2% in a direct comparison with semaglutides 13.7%. Its second receptor, GIP, separates tirzepatide from approved single-receptor GLP-1 drugs and helps explain the larger population-level weight loss. That 20.9% came from participants averaging about 105 kg at a BMI of 38, most of whom were sedentary

Consistent Delivery: Provides steady, sustained peptide delivery to target tissues